Akeso announces oral presentation featuring promising clinical data of Cadonilimab (PD-1/CTLA-4 BsAbs, AK104) for the first-line treatment of R/M cervical cancer at ASCO 2022 ...Middle East

HONG KONG, June 5, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, released updated results of Cadonilimab (PD-1/CTLA-4...

Hence then, the article about akeso announces oral presentation featuring promising clinical data of cadonilimab pd 1 ctla 4 bsabs ak104 for the first line treatment of r m cervical cancer at asco 2022 was published today ( Monday 06/06/2022 - 04:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso announces oral presentation featuring promising clinical data of Cadonilimab (PD-1/CTLA-4 BsAbs, AK104) for the first-line treatment of R/M cervical cancer at ASCO 2022 )

Also on site :

• Man arrested on suspicion of fatal shooting in Huntington Beach
• Danish authorities banned from using Bluetooth at work – media
• ‘China Beach’ and ‘CSI’ Star Marg Helgenberger Is a Stunning Strawberry Blonde at 67